• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Photodynamic therapy for choroidal neovascularization in young adult patients.

作者信息

Ehrlich Rita, Kramer Michal, Rosenblatt Irit, Weinberger Dov, Mimouni Karin, Priel Ethan, Axer-Siegel Ruth

机构信息

Department of Ophthalmology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, 49100, Israel.

出版信息

Int Ophthalmol. 2010 Aug;30(4):345-51. doi: 10.1007/s10792-010-9346-3. Epub 2010 Feb 2.

DOI:10.1007/s10792-010-9346-3
PMID:20127140
Abstract

We report our experience with photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) in young adult patients. This was a retrospective study of young adults with CNV treated with PDT. Data collected included age, diagnosis, type and size of CNV, number of treatments, visual outcome, and side effects. Ten patients (11 eyes) were included in the study (mean age 27.2 +/- 13.3 years). Etiologies included multifocal choroiditis (3 eyes), idiopathic CNV (5 eyes), central serous chorioretinopathy (1 eye), and toxoplasma (2 eye). The mean number of treatments was 2 +/- 0.7 and the mean follow-up time was 13.1 +/- 9.5 months. Initial visual acuity (VA) ranged from 20/25 to 20/1,200 (mean logMAR 0.6 +/- 0.5), and improved to 20/20 to 20/250 (mean logMAR 0.46 +/- 0.4) (P = 0.51). Of the four eyes that received additional treatment with oral steroids, one of which also received intravitreal bevacizumab (Avastin) injections, all had visual acuity improvement of 2 or more lines, while only two of seven eyes that received PDT alone showed such improvement. PDT can improve visual outcome in a subgroup of young patients with subfoveal CNV especially when supplemented with oral steroid and bevacizumab injections.

摘要

相似文献

1
Photodynamic therapy for choroidal neovascularization in young adult patients.
Int Ophthalmol. 2010 Aug;30(4):345-51. doi: 10.1007/s10792-010-9346-3. Epub 2010 Feb 2.
2
Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.贝伐单抗与光动力疗法治疗多灶性脉络膜炎性脉络膜新生血管的比较
Arch Ophthalmol. 2010 Sep;128(9):1100-3. doi: 10.1001/archophthalmol.2010.205.
3
ANTIANGIOGENICS IN CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH LASER IN CENTRAL SEROUS CHORIORETINOPATHY.抗血管生成药物在中心性浆液性脉络膜视网膜病变激光治疗相关脉络膜新生血管中的应用
Retina. 2016 May;36(5):901-8. doi: 10.1097/IAE.0000000000000804.
4
Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.玻璃体腔内注射贝伐单抗联合维替泊芬光动力疗法治疗年龄相关性黄斑变性脉络膜新生血管
Retina. 2008 May;28(5):675-81. doi: 10.1097/IAE.0b013e31816b316e.
5
Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis.联合光动力疗法和贝伐单抗治疗弓形虫相关性脉络膜新生血管。
Indian J Ophthalmol. 2011 Jan-Feb;59(1):62-4. doi: 10.4103/0301-4738.73728.
6
Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).玻璃体内注射贝伐单抗(阿瓦斯汀)联合维替泊芬光动力疗法治疗年龄相关性黄斑变性相关脉络膜新生血管(IBeVe研究)
Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1273-80. doi: 10.1007/s00417-007-0557-x. Epub 2007 Feb 28.
7
Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.贝伐单抗(阿瓦斯汀)和雷珠单抗(兰尼单抗)用于多灶性脉络膜炎性脉络膜新生血管形成
Retina. 2009 Jan;29(1):8-12. doi: 10.1097/IAE.0b013e318187aff9.
8
Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration.贝伐单抗治疗年龄相关性黄斑变性以外原因引起的黄斑中心凹下脉络膜新生血管。
Arch Ophthalmol. 2008 Jul;126(7):941-5. doi: 10.1001/archopht.126.7.941.
9
Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.年龄相关性黄斑变性中脉络膜新生血管单独光动力疗法及光动力疗法联合玻璃体腔注射贝伐单抗后的图形视网膜电图结果
Doc Ophthalmol. 2009 Aug;119(1):37-42. doi: 10.1007/s10633-009-9167-8. Epub 2009 Feb 19.
10
Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis.玻璃体内注射贝伐单抗治疗葡萄膜炎继发的难治性脉络膜新生血管(CNV)。
Graefes Arch Clin Exp Ophthalmol. 2008 Dec;246(12):1685-92. doi: 10.1007/s00417-008-0906-4. Epub 2008 Aug 6.

引用本文的文献

1
High‑dose aflibercept injection has striking effects on myopic choroidal neovascularization.高剂量阿柏西普注射对近视性脉络膜新生血管有显著疗效。
Exp Ther Med. 2023 May 9;25(6):301. doi: 10.3892/etm.2023.12000. eCollection 2023 Jun.
2
Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy.葡萄膜炎相关性脉络膜新生血管的管理:从发病机制到治疗
J Ophthalmol. 2014;2014:450428. doi: 10.1155/2014/450428. Epub 2014 Apr 27.
3
Intravitreal bevacizumab as a primary treatment for idiopathic choroidal neovascularization.

本文引用的文献

1
Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.贝伐单抗(阿瓦斯汀)和雷珠单抗(兰尼单抗)用于多灶性脉络膜炎性脉络膜新生血管形成
Retina. 2009 Jan;29(1):8-12. doi: 10.1097/IAE.0b013e318187aff9.
2
Intravitreal bevacizumab in inflammatory ocular neovascularization.玻璃体内注射贝伐单抗治疗炎性眼部新生血管形成
Am J Ophthalmol. 2008 Sep;146(3):410-416. doi: 10.1016/j.ajo.2008.05.024. Epub 2008 Jul 10.
3
Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series.
玻璃体内注射贝伐单抗作为特发性脉络膜新生血管的主要治疗方法。
Middle East Afr J Ophthalmol. 2011 Jul;18(3):220-3. doi: 10.4103/0974-9233.84051.
光动力疗法联合玻璃体内注射曲安奈德治疗点状内层脉络膜病变继发或特发性脉络膜新生血管:前瞻性系列研究的一年结果
Retina. 2008 Jan;28(1):71-80. doi: 10.1097/IAE.0b013e31815e9339.
4
Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration.静脉注射贝伐单抗可使除年龄相关性黄斑变性以外的其他疾病继发的脉络膜新生血管消退。
Am J Ophthalmol. 2008 Feb;145(2):257-266. doi: 10.1016/j.ajo.2007.09.025. Epub 2007 Dec 11.
5
Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization.玻璃体内注射贝伐单抗(阿瓦斯汀)作为炎症性脉络膜新生血管的主要治疗方法。
Retina. 2007 Nov-Dec;27(9):1180-6. doi: 10.1097/IAE.0b013e31815e9834.
6
Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.玻璃体内注射贝伐单抗治疗黄斑中心凹下特发性脉络膜新生血管
Arch Ophthalmol. 2007 Nov;125(11):1487-92. doi: 10.1001/archopht.125.11.1487.
7
Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.玻璃体内注射贝伐单抗(阿瓦斯汀)用于治疗继发于中心性浆液性脉络膜视网膜病变、点状内层脉络膜病变或特发性的脉络膜新生血管。
Am J Ophthalmol. 2007 Jun;143(6):977-983. doi: 10.1016/j.ajo.2007.02.039. Epub 2007 Apr 24.
8
Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone.玻璃体内注射贝伐单抗治疗既往球后注射曲安奈德后发生的特发性脉络膜新生血管化。
Am J Ophthalmol. 2007 Mar;143(3):507-10. doi: 10.1016/j.ajo.2006.10.050. Epub 2006 Dec 8.
9
Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy.光动力疗法联合全身糖皮质激素治疗点状内层脉络膜病变继发脉络膜新生血管
Eye (Lond). 2008 Apr;22(4):528-33. doi: 10.1038/sj.eye.6702688. Epub 2007 Jan 19.
10
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.雷珠单抗与维替泊芬治疗新生血管性年龄相关性黄斑变性的比较。
N Engl J Med. 2006 Oct 5;355(14):1432-44. doi: 10.1056/NEJMoa062655.